RA
TRDA icon

Royce & Associates’s Entrada Therapeutics TRDA Stock Holding History

Royce & Associates’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$610K Sell
82,902
-37,943
-31% -$364K ﹤0.01% 698
2026
Q1 		$1.53M Sell
120,845
-126,302
-51% -$1.45M 0.02% 617
2025
Q4 		$2.54M Sell
247,147
-98,360
-28% -$829K 0.03% 565
2025
Q3 		$2M Buy
345,507
+122,256
+55% +$715K 0.02% 593
2025
Q2 		$1.5M Buy
+223,251
New +$1.8M 0.02% 634

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Royce & Associates's TRDA Position: Q2 2026 in Review

Royce & Associates reduced its Entrada Therapeutics (TRDA) stake by 31% in Q2 2026, selling an estimated $364K and leaving 82,902 shares worth $610K. The position accounts for ﹤0.01% of the portfolio, ranked #698.

Royce & Associates first reported a position in TRDA in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.54M in Q4 2025. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Royce & Associates held 82,902 shares of Entrada Therapeutics worth $610K as of Q2 2026.
  • Royce & Associates sold 37,943 Entrada Therapeutics shares in Q2 2026, an estimated $364K.
  • Entrada Therapeutics made up ﹤0.01% of Royce & Associates's portfolio in Q2 2026, its #698 holding.
  • Royce & Associates first reported a position in Entrada Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Royce & Associates's Entrada Therapeutics position peaked at $2.54M in Q4 2025.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.